Claire Brillac
Vitry-sur-seine, 94403, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics.
Journal: Cancer chemotherapy and pharmacology
Published: July 06, 2025
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 24, 2021
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: February 12, 2021
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
Journal: Blood cancer journal
Published: October 28, 2020
Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
Journal: CPT: pharmacometrics & systems pharmacology
Published: May 27, 2020
Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 23, 2019
Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.
Journal: Cancer science
Published: September 06, 2018
Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates.
Journal: Journal of clinical pharmacology
Published: September 26, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026